What is the appropriate workup for a suspected pulmonary embolism?

Workup for Suspected Pulmonary Embolism

Begin with clinical probability assessment using a validated scoring system (Wells or revised Geneva), then proceed with D-dimer testing or imaging based on risk stratification—never order D-dimer in high-probability patients, and always start therapeutic anticoagulation immediately in intermediate or high-probability cases before imaging confirmation. 1, 2

Step 1: Initial Clinical Assessment

Assess hemodynamic stability first. Shock or hypotension (systolic BP <90 mmHg or ≥40 mmHg drop lasting >15 minutes) identifies massive PE requiring emergent management. 2

Key Clinical Features to Document

• Respiratory rate: Tachypnea >20 breaths/min is present in most PE patients and significantly raises probability. 1, 2
• Heart rate: Tachycardia ≥95 beats/min increases clinical probability. 2
• Oxygen saturation: Up to 40% of PE patients have normal SaO₂—never use normal oxygen saturation to rule out PE. 2
• Clinical presentation patterns: 1
  • Sudden collapse with raised jugular venous pressure (faintness/hypotension)
  • Pulmonary hemorrhage syndrome (pleuritic pain and/or hemoptysis)
  • Isolated dyspnea (no cough, sputum, or chest pain)

High-Risk Populations Where PE is Easily Missed

• Severe cardiorespiratory disease 1
• Elderly patients 1
• Patients with isolated breathlessness as the only symptom 1

Step 2: Clinical Probability Stratification

Use Wells score or revised Geneva score to classify patients into low, intermediate, or high probability. 1, 2

Wells Score Key Components

• Recent immobilization ≥3 days or surgery within 4 weeks: 1.5 points 2
• Active malignancy: 1 point 2
• Clinical signs of DVT 1
• Previous proven DVT or PE 1
• Heart rate >100 bpm 2
• Hemoptysis 2
• PE more likely than alternative diagnosis: 3 points 2

High Wells score (>6 points) corresponds to PE prevalence of 36-50%. 2

Revised Geneva Score Key Components

• Previous DVT or PE 2
• Heart rate 75-94 bpm: 3 points; ≥95 bpm: 5 points 2
• Recent surgery or fracture within 1 month: 2 points 2
• Active malignancy: 2 points 2
• Unilateral leg pain: 3 points 2
• Pain on deep palpation with unilateral edema: 4 points 2
• Hemoptysis 2
• Age >65 years 2

Step 3: Risk-Stratified Diagnostic Pathway

Low Clinical Probability

Apply PERC (Pulmonary Embolism Rule-Out Criteria) first. If all eight criteria are met, stop the workup—no further testing needed. 1, 2

PERC Criteria (all must be met):

• Age <50 years 2
• Heart rate <100 bpm 2
• Oxygen saturation ≥95% on room air 2
• No hemoptysis 2
• No estrogen use 2
• No prior DVT or PE 2
• No unilateral leg swelling 2
• No surgery/trauma requiring hospitalization within 4 weeks 2

If any PERC criterion is positive, obtain high-sensitivity D-dimer (ELISA or turbidimetric assay with ≥95% sensitivity). 1, 2

• For patients ≤50 years: Use standard cutoff <500 ng/mL 1, 2
• For patients >50 years: Use age-adjusted cutoff (age × 10 ng/mL) 1, 2

A negative D-dimer excludes PE with 3-month thromboembolic risk <1%—no imaging needed. 1, 2

A positive D-dimer requires immediate CTPA. 1, 2

Intermediate Clinical Probability

Do not use PERC rule. Obtain high-sensitivity D-dimer first. 2

• Use same age-adjusted thresholds as low-probability pathway. 1, 2
• Negative D-dimer excludes PE without imaging. 1, 2
• Positive D-dimer requires CTPA. 1, 2

Start therapeutic anticoagulation immediately while awaiting imaging results. 1, 2

High Clinical Probability

Proceed directly to CTPA—do not order D-dimer. D-dimer testing adds no diagnostic value in high-probability patients and delays care. 1, 2

Initiate therapeutic anticoagulation before imaging confirmation. 1, 2

Step 4: Imaging Selection

CT Pulmonary Angiography (CTPA)

CTPA is the first-line imaging modality for hemodynamically stable patients. 1, 2

• In low or intermediate probability patients, a negative CTPA definitively rules out PE—no further testing needed. 2
• In intermediate or high probability patients, a segmental or more proximal filling defect confirms PE. 2
• Sensitivity for segmental or larger emboli: 83-95%. 2
• Radiation exposure: 3-10 mSv. 2

Ventilation-Perfusion (V/Q) Scanning

Use V/Q scanning when CTPA is contraindicated or unavailable. 1, 2

Indications for V/Q over CTPA:

• Severe contrast allergy 2
• Significant renal impairment 2
• Pregnancy (to reduce breast radiation) 2
• Hyperthyroidism 2

V/Q Interpretation:

• Normal perfusion scan excludes PE. 1, 2
• High-probability scan + high clinical probability confirms PE. 1, 2
• All other combinations require CTPA or pulmonary angiography. 1, 2

Radiation dose: ~2 mSv (lower than CTPA). 2

SPECT V/Q reduces inconclusive results to <3% (vs ~50% with planar imaging). 2

Lower-Extremity Compression Ultrasound

Perform ultrasound before or alongside CTPA when:

• Clinical DVT signs are present 2
• Renal failure 2
• Contrast allergy 2
• Pregnancy 2

Detection of proximal DVT is sufficient to start anticoagulation without further PE imaging. 1, 2

A normal ultrasound does not exclude PE (only 30-50% of PE patients have detectable DVT)—proceed to lung imaging if D-dimer is elevated. 2

Step 5: Management of Massive (Hemodynamically Unstable) PE

Massive PE is defined by systolic BP <90 mmHg (or ≥40 mmHg drop lasting >15 min) or shock requiring vasopressors. 2

Diagnostic Approach

• If patient can be safely transported, obtain emergent CTPA. 2
• If transport is unsafe, perform bedside echocardiography to assess right-ventricular dysfunction. 2
• RV dysfunction on echo confirms high-risk PE and justifies emergency reperfusion therapy without waiting for CTPA. 2

Immediate Anticoagulation

Initiate unfractionated heparin immediately:

• Initial bolus: 80 IU/kg IV push 1, 2, 3
• Maintenance infusion: 18 IU/kg/hour 1, 2, 3
• Target aPTT: 1.5-2.5 times control (45-75 seconds) 1, 3

aPTT Monitoring Schedule:

• First check: 4-6 hours after initial bolus 1, 3
• After any dose change: 6-10 hours later 1, 3
• Once therapeutic: daily 1, 3

Step 6: Anticoagulation for Non-Massive PE

Low-molecular-weight heparin (LMWH) is preferred over unfractionated heparin for non-massive PE—equivalent efficacy and safety with greater ease of use. 2

Alternative: Direct oral anticoagulants (DOACs) such as rivaroxaban 15 mg twice daily for 21 days, then 20 mg once daily—provide immediate therapeutic anticoagulation without heparin bridging. 3

Warfarin transition:

• Start warfarin 5-10 mg daily simultaneously with heparin 1, 3
• Continue heparin minimum 5 days and until INR ≥2.0 for at least 24 hours 1, 3
• Target INR: 2.0-3.0 1, 3

Critical Pitfalls to Avoid

• Never order D-dimer without first determining clinical probability—leads to excessive false-positive imaging. 2
• Never order D-dimer in high-probability patients—provides no reliable exclusion and wastes time. 1, 2
• Never use the standard 500 ng/mL D-dimer cutoff in patients >50 years—specificity falls to ~10% in patients >80 years. Always use age-adjusted thresholds. 1, 2
• Never rely on normal oxygen saturation to rule out PE—up to 40% of PE patients have normal SaO₂. 2
• Never skip imaging in high-probability patients with negative D-dimer—negative predictive value is insufficient. 2
• Never make CTPA the first test in low or intermediate probability patients—D-dimer can safely exclude PE in 30-50% of cases, reducing radiation and cost. 2
• Never order V/Q scan when chest X-ray is abnormal or patient has chronic cardiopulmonary disease—results are likely non-diagnostic. 2
• Never delay anticoagulation in intermediate or high-probability patients—start heparin immediately before imaging confirmation. 1, 2

Special Populations

Pregnancy

• Prefer V/Q scanning over CTPA to minimize breast radiation. 2
• Perform lower-extremity ultrasound first to avoid any radiation if DVT can be confirmed. 2
• Both V/Q and CTPA are considered safe during pregnancy. 2

Cancer Patients

• Baseline D-dimer is often elevated (specificity 18-21%), but a negative D-dimer still safely excludes PE when combined with low or intermediate clinical probability. 2